We are currently making some changes to how orders are placed and because of this there will be a
short disruption period affecting order processing. Thank you for your patience while we work to
operate as smoothly as possible (November 14, 2023).
SIGi001-A-16
SIGi001-A-9 Bi-Allelic MAPT HA-tag
Gene-edited iPSC line
Purchases have been temporarily disabled, as we are transitioning sales and distribution.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | SIGi001-A-16 |
| Alternative name(s) |
SIGi001-A-9 Bi-Allelic MAPT HA-tag
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
SIGi001-A-3 (iPSC0028 MAPT P301L C4) SIGi001-A-4 (iPSC0028 MAPT P301L D4) SIGi001-A-5 (iPSC0028 MAPT P301S 1C9C4) SIGi001-A-6 (iPSC0028 MAPT P301S 1B9C9) SIGi001-A-7 (iPSC0028 MAPT P301S 2G2B7) SIGi001-A-12 (iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570) SIGi001-A-8 (iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7) SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) SIGi001-A-10 (iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8) SIGi001-A-11 (iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118) SIGi001-A-1 (iPSC0028 SLC17A7/GFP E3) SIGi001-A-2 (iPSC0028 SLC17A7/GFP C3) SIGi001-A-14 (SIGi001-A Bi-Allelic MAPT HA-tag) SIGi001-A-15 (SIGi001-A Dox inducible NGN2) SIGi001-A-17 (SIGi001-A-9 Dox inducible NGN2) SIGi001-A-18 (SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5) SIGi001-A-19 (SIGi001-A-12 Dox inducible NGN2) |
| Notes | SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) having a HA-tag at the C-terminal end of MAPT, Bi-Allelic |
Provider |
|
| Depositor | Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
| hPSCreg | SIGi001-A-16 |
| BioSamples | SAMEA6080815 |
| CLO | CLO_0103295 |
| Cellosaurus | CVCL_A7GT |
| Wikidata | Q107116926 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | (not in EBiSC, see SIGi001-A in hPSCreg) |
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4447434 |
hIPSC Derivation#
General |
|
|
More source cell information can be found in the parental cell line
SIGi001-A in hPSCreg.
|
|
| Passage number reprogrammed | +15 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Unknown |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| SSEA-1 |
No |
Morphology pictures
Differentiation Potency
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: +15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Disease/phenotype related modifications |
|